The disappointing trial caused Incyte stock to drop more than 19 percent on Friday; Merck shares were down near 3 percent, though that merely matched the selloff in the stock market. "We are disappointed that this study did not …
The firm also noted that the stock is trading at a discount to peers in a relative ...
Argentiere Capital Ag sold 25,000 shares as Incyte Corp (INCY)’s stock declined 11.25%. The Argentiere Capital Ag …
Following the failure, Incyte stock lost more 19% on Friday. Merck shares drop by almost 3%. In a press release, …
Cibc Asset Mngmt, Ontario – Canada-based fund reported 26,281 shares ... Parallax Volatility Advisers Ltd Partnership, …
We saw evidence in April 2017, when the FDA issued a complete response letter for Olumiant: Incyte stock fell more than twice as much as Lilly's did on the bad news. A similar effect followed in August, after the two companies announced …
Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3. Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.